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Background: Molecular signaling during chondrogenic differentiation of mesenchymal stem cells (MSC) is poorly
understood.
Results: Knockdown of sirtuin-1 (SIRT1) in MSC induced inhibition of chondrogenesis, Sox9 expression, up-regulation of
nuclear factor-B (NF-B) phosphorylation and acetylation, and NF-B-dependent pro-inflammatory enzymes.
Conclusion: SIRT1 supports chondrogenic differentiation of MSCs by Sox9 activation and NF-B deacetylation.
Significance: These findings may be essential for improving cartilage tissue regeneration.
Sirtuin-1 (SIRT1), NAD-dependent deacetylase, has been
linked to anabolic effects in cartilage, although the mechanisms
of SIRT1 signaling during differentiation of mesenchymal stem
cells (MSCs) to chondrocytes are poorly understood. Therefore,
we investigated the role of SIRT1-mediated signaling during
chondrogenic differentiation of MSCs in vitro. High density and
alginate cultures of MSCs were treated with chondrogenic
induction medium with/without the SIRT1 inhibitor nicotin-
amide, antisense oligonucleotides against SIRT1 (SIRT1-ASO),
IL-1, and/or resveratrol. Transient transfection of MSCs with
SIRT1-antisense oligonucleotides, nicotinamide, and IL-1
inhibited chondrogenesis-induced down-regulation of carti-
lage-specific proteins, cartilage-specific transcription factor
Sox9, and enhanced NF-B-regulated gene products involved
in the inflammatory and degradative processes in cartilage
(MMP-9, COX-2, and caspase-3), and NF-B phosphorylation,
acetylation, and activation of IB kinase. In contrast, the
SIRT1 activator resveratrol or BMS-345541 (inhibitor of IKK)
inhibited IL-1- and NAM-induced suppression of cartilage-
specific proteins, Sox9, and up-regulation of NF-B-regulated
gene products. Moreover, SIRT1 was found to interact directly
with NF-B and resveratrol-suppressed IL-1 and NAM but not
SIRT1-ASO-induced NF-B phosphorylation, acetylation, and
activation of IB kinase. Knockdown of SIRT1 by mRNA abol-
ished the inhibitory effects of resveratrol on inflammatory and
apoptotic signaling and Sox9 expression, suggesting the essen-
tial role of this enzyme. Finally, the modulatory effects of res-
veratrol were found to be mediated at least in part by the asso-
ciation between SIRT1 and Sox9. These results indicate for the
first time that SIRT1 supports chondrogenic development of
MSCs at least in part through inhibition/deacetylation of NF-B
and activation of Sox9.
Mesenchymal stem cells (MSCs)2 are multipotent cells and
can differentiate into different specialized cell types, like chon-
drocytes, osteocytes, or adipocytes in vitro (1–3). Adult MSCs
are easy to isolate from bone marrow or adipose tissue and
expand in vitro, and they provide a suitable source of cells for
tissue engineering and regenerative medicine (2, 4). Moreover,
adult MSCs are a practicable alternative and an ethically
accepted source of multipotent cells compared with the limited
use of embryonic or fetal stem cells (5, 6). Development of car-
tilage tissue from MSCs commences with condensation and
differentiation (7). Chondrocytes then produce the cartilage-
specific extracellular matrix (ECM) proteins that provide this
tissue with its unique mechanical properties required for resis-
tance to adequate loading.
Several other investigations and our laboratory have clearly
demonstrated that three-dimensional culture models of mes-
enchyme-derived cells are suitable to develop and differentiate
MSCs toward chondrocytes as they closely replicate the exten-
sive cell-matrix interactions that occur in vivo (2, 8 –10). We
have already adopted high density and alginate cultures as in
vitro models to culture MSCs derived from mouse limb buds,
adult MSCs, and chondrocytes and to develop cartilage tissue
(2, 10 –14). However, age-related arthritic disease, osteoarthri-
tis, and rheumatoid arthritis are involved in the degenerative
changes in the joint, leading to loss of function, pain, and sig-
nificant disability (15). It is known that articular cartilage is an
avascular, alymphatic, and aneural tissue with bradytrophic
characteristics and a very poor capacity for self-repair and
regeneration (16, 17). This weakness in cartilage repair capacity
highlights the need for novel treatments using tissue engineer-
ing and regenerative medicine and new regenerative strategies
involving stimulation of articular cartilage repair in vivo (18).
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Indeed, it has been shown that adult MSC-like progenitors also
exist in the cartilage tissue and that their abundance in arthritic
cartilage is elevated (19). The lack of regeneration in cartilage
can be due to the ongoing inflammatory microenvironment
that occurs during the course of osteoarthritis and rheumatoid
arthritis. It is therefore important to block the pro-inflamma-
tory cytokine-induced cartilage degeneration and at the same
time create a more suitable microenvironment for the chon-
drogenesis of MSC-like progenitors (20).
Resveratrol (3,5,4-trihydroxy-trans-stilbene) is a phyto-
alexin (polyphenolic compound) found in the skin of red
grapes, cranberries, peanuts, and root extracts of the weed Poly-
gonum cuspidatum (21). Several reports have demonstrated
that resveratrol has anti-inflammatory, antioxidant, and antitu-
mor activity in cancer cell lines derived from human and animal
tumors (22–24). One of the most important and functional
novel molecular targets of resveratrol is sirtuin-1 (SIRT1), a
member of the sirtuin family of nicotinamide adenine dinucle-
otide (NAD)-dependent deacetylases, which is found to be an
anti-aging gene (25, 26). SIRT1 is able to de-acetylate many
different transcription factors in the nucleus such as p53,
NF-B, myogenic differentiation, high mobility group I, E2F
transcription factor, and forkhead box O, thus playing an essen-
tial role in cell differentiation, cell survival, tumorigenesis,
inflammation, and metabolism (27–31). Moreover, SIRT1 tar-
gets chromatin (histones) as well as nonchromatin proteins in
the cells, has been linked to transcriptional silencing, and
appears to play a key role in inflammation (32, 33). More
recently, several reports have shown that normal cartilage
homeostasis requires enzymatically active SIRT1 protein in
vivo (34 –36).
In the past, it has been shown that SIRT1 plays an essential
role in a variety of tissue development and diseases. However,
still little is known about its role in MSC differentiation. The
purpose of this study was therefore to examine whether SIRT1,
at least in part, regulates differentiation of MSCs to chondro-
cytes in vitro.
EXPERIMENTAL PROCEDURES
Antibodies—Acetylated lysine (Ac-K-103) antibody was pur-
chased from Cell Signaling Technology (Danvers, MA). Mono-
clonal and polyclonal antibody to SIRT1 was purchased from
Abcam PLC (Cambridge, UK). Polyclonal anti-collagen type II,
monoclonal anti-adult cartilage-specific proteoglycan (CSPGs),
and alkaline phosphatase-linked sheep anti-mouse and sheep
anti-rabbit secondary antibodies for immunoblotting were
from Millipore (Schwalbach, Germany). Antibodies to active
caspase-3 and MMP-9 were from R&D Systems, Inc. (Heidel-
berg, Germany). Cyclo-oxygenase-2 antibody was obtained
from Cayman Chemical (Ann Arbor, MI). Anti-phospho-spe-
cific p65 (NF-B)/(Ser-536) and anti-phospho-specific IB
(Ser-32/36) were obtained from Cell Technology, Inc. (Beverly,
MA). Anti-IKK- and anti-IKK- antibodies were obtained
from Imgenex (Hamburg, Germany). Monoclonal anti-Sox9,
monoclonal anti-CD105, monoclonal anti-CD90, monoclonal
anti-CD45, and monoclonal anti-CD34 were purchased from
Acris Antibodies GmbH (Hiddenhausen, Germany). Monoclo-
nal anti--actin was purchased from Sigma. Secondary anti-
bodies used for fluorescence labeling were purchased from
Dianova (Hamburg, Germany). All antibodies were used at con-
centrations and dilutions recommended by the manufacturer.
Growth Media, Chemicals, Cytokines—Whole cell culture
growth medium consisting of DMEM/Ham’s F-12 1:1, 10%
FBS, 1% partricin solution, 1% penicillin/streptomycin solution
(10,000 IU/10,000 IU), 75 g/ml ascorbic acid, 1% essential
amino acids, and 1% glutamine were purchased from Seromed
(Munich, Germany). BMS-345541, NAM, and resveratrol were
purchased from Sigma. Resveratrol was prepared as a 1000 M
solution in ethanol and then further diluted in cell culture
medium. The final concentration of ethanol did not, in any case,
exceed 0.5%. Further dilutions were made in cell culture
medium to achieve the final working concentrations. Interleu-
kin-1 (IL-1) was purchased from Acris antibodies GmbH
(Herold, Germany).
Chondrocyte and Mesenchymal Stem Cell Culture—Primary
human chondrocytes (catalog no. 121 0211) and human mes-
enchymal stem cells (catalog no. 121 0911 HMSC-bm) were
obtained from Provitro (Berlin, Germany). Specimens of knee
joint cartilage and human bone marrow were obtained with
total informed consent and approval of the ethics committee of
the Charité-University Medical School Berlin (Germany). Cells
were seeded at a density of 300,000 cells/T75 flask, cultured in
whole cell culture medium, and passaged at 70 – 80% conflu-
ence. Passages 3– 4 were used for the experiments. Character-
ization of MCS was performed by immunofluorescent evalua-
tion of a set of defined markers (CD105, CD90, CD45, and
CD34) (37). To quantify the population for each marker, the
number of cells with positive labeling was determined by scor-
ing 300 cells from 10 different microscopic fields within the
stained slides.
Chondrogenic Differentiation in High Density and Alginate
Bead Culture—Chondrogenic differentiation of MSC was per-
formed in high density culture and in alginate bead culture as
described previously (2, 10). We have used alginate bead culture
complementary to high density culture, because in alginate
bead culture the cells have strong chondrogenic potential; addi-
tionally it is fairly easy to retrieve the cells from alginate to
perform additional experiments such as immunoprecipitation,
immunofluorescence, and MTT assays. For high density cul-
ture, a 10-l drop of 1 million cells was plated on a cellulose
filter on top of a steel mesh bridge. Cell culture medium
reached the filter medium interface, and cells were nurtured
through diffusion. This model allows the cells to aggregate, and
after 1 day in culture, the cells formed a three-dimensional pel-
let on the filter. For alginate bead culture, 2 million cells/ml
alginate were encapsulated in sterile alginate (2.5% in 0.15 M
NaCl solution) by pipetting single drops into a 100 mM CaCl2
solution. At contact with the CaCl2 solution, the alginate drops
polymerized forming a round and stable bead. To ensure ade-
quate polymerization, beads were incubated with 100 mM
CaCl2 solution for 10 min. Subsequently, beads were rinsed
three times in 0.15 M NaCl solution followed by washing two
times with complete cell culture medium to remove excess
NaCl/CaCl2 solution and were transposed to a new Petri dish.
Chondrogenic differentiation medium was prepared as
described by Pittenger et al. (1) consisting of DMEM base
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medium, D-()-glucose 0.35 g/100 ml, ITS  1 liquid media
supplement (10 g/ml insulin, 5.5 g/ml transferrin, 5 ng/ml
selenium, 0.5 mg/ml bovine albumin, 4.7 g/ml linoleic acid
(Sigma, catalog no. I-2521)), 0.1 mM ascorbate 2-phosphate
(Sigma catalog no. A-8960), 107 M dexamethasone (Sigma cat-
alog no. D-8893), penicillin/streptomycin solution (10,000
IU/10,000 IU/100 ml). Ten ng/ml human TGF1 (Acris Anti-
bodies GmbH, Germany) was added freshly to the medium
before each medium change, and medium changes were made
three times/week. The cultures were incubated for 14 days in a
humidified incubator at 37 °C in an atmosphere of 95% air and
5% CO2 before further evaluation.
Antisense and Lipofectin-mediated Transfection—Transient
transfection of primary human chondrocytes, chondrogenic
differentiated MSCs, and MSCs undergoing chondrogenesis
was performed as described previously (38). Phosphorothio-
ated antisense oligonucleotide derived from mRNA nucleotide
sequence of sirtuin-1 gene (SIRT1-ASO) (sequence 5-GTAT-
TCCACATGAAACAGACA-3) and control sense oligonu-
cleotides (SIRT1-SO) (sequence 5-TGTCTGTTTCATGTG-
GAATAC-3) used in the experiments were synthesized by
Eurofins (MWG/Operon, Ebersberg, Germany). SIRT1-ASO
and SIRT1-SO were phosphorothioate-modified to protect
them from the cell nucleases. Cells in monolayer culture were
transfected by incubation with 0.5 M SIRT1-ASO or
SIRT1-SO and 10 l/ml Lipofectin transfection reagent (Invit-
rogen) in serum-starved medium (3% FCS) for 24 h before start-
ing the respective experiments. All monolayer transfection
experiments were carried out on 50 – 60% confluent monolayer
cultures. For transfection of high density and alginate bead cul-
tures, MSCs (1  106) were either untreated or pretreated in
slurry with resveratrol (5 M) for 4 h in serum-starved medium.
After this treatment, whole cells were transferred to high den-
sity or alginate cultures and either served as controls (no treat-
ment) or were transfected with various concentrations (0.1, 0.5,
1, and 5 M) of SIRT1-ASO or SIRT1-SO in the presence of
Lipofectin (10 l/ml) transfection reagent in chondrogenic
induction medium for 14 days. Culture medium with SIRT1-
ASO or SIRT1-SO was changed every 3 days.
Electron Microscopic Evaluation—To evaluate chondrogenic
ultrastructure, transmission electron microscopy was performed
as described previously in detail (39). Briefly, cultures were fixed
for 1 h in Karnovsky fixative, post-fixed in 1% OsO4 solution, dehy-
drated in serial alcohol dilutions, and embedded in Epon (Plano,
Germany). Following this, ultrathin cuts were made on a Reichert-
Ultracut E, contrasted with a mixture of 2% uranyl acetate/lead
citrate, and evaluated with a Zeiss 10 transmission electron micro-
scope (Institute of Pharmacology, Berlin, Germany).
Quantification of Apoptotic Cell Death—Ultrathin sections
of the cultures were prepared and evaluated with a transmission
electron microscope. To quantify the apoptotic cells, the num-
ber of cells with morphological features of apoptotic cell death
was determined by scoring 100 cells from 25 different micro-
scopic fields.
Western Blot Analysis—Western blotting of whole cell lysates
was performed as described previously (40, 41). Briefly, whole
cell lysate proteins were extracted with lysis buffer (50 mM Tris-
HCl, pH 7.2, 150 mM NaCl, 1% (v/v) Triton X-100, 1 mM sodium
orthovanadate, 50 mM sodium pyrophosphate, 100 mM sodium
fluoride, 0.01% (v/v) aprotinin, 4 g/ml pepstatin A, 10 g/ml
leupeptin, 1 mM phenylmethylsulfonyl fluoride, PMSF) on ice for
30 min, and total protein content was measured. Subsequently,
samples were reduced with 2-mercaptoethanol, and total protein
concentrations were adjusted. After separation of proteins by
SDS-PAGE under reducing conditions, samples were blotted onto
a membrane using a transblot apparatus (Bio-Rad) and blocked for
2 h in 5% (w/v) skimmed milk powder in phosphate-buffered
saline, 0.1% Tween 20. Membranes were incubated overnight with
the primary antibody at a 1:1000 dilution in blocking buffer at 4 °C
on a shaker. Incubation with the secondary antibody conjugated
with alkaline phosphatase was performed for 90 min. After wash-
ing the membranes three times in 0.1 M Tris, pH 9.5, containing
0.05 M MgCl2 and 0.1 M NaCl, specific antigen-antibody com-
plexes were detected using nitro blue tetrazolium and 5-bromo-4-
chloro-3-indoylphosphate (p-toluidine salt; Pierce) as substrates
for alkaline phosphatase.
Immunoprecipitation of SIRT1/p65 Acetylation and SIRT1/
Sox9 Assay—To evaluate the effect of resveratrol on IL-1-,
NAM-, and SIRT1-ASO-induced p65 acetylation and Sox9
expression, endogenous protein interactions from high density
and alginate cultures were evaluated by co-immunoprecipita-
tion experiments using SIRT1, anti-acetyl-lysine, and Sox9
antibodies. After 14 days, whole cell extracts were washed and
lysed to prepare whole cell lysates. Whole cell extracts were
precleared by incubating with 25 l of either normal rabbit IgG
serum or mouse IgG serum and protein A/G-Sepharose beads.
The precleared whole cell extract was incubated with primary
antibodies (anti-SIRT1 or anti-Sox9) and diluted in wash buffer
(0.1% Tween 20, 150 mM NaCl, 50 mM Tris-HCl, pH 7.2, 1 mM
CaCl2, 1 mM MgCl2, and 1 mM PMSF) for 2 h at 4 °C and finally
with protein A/G-Sepharose beads for 1 h at 4 °C. After incu-
bation, immunocomplexes were washed with lysis buffer,
boiled with SDS sample buffer for 5 min, resolved on SDS-
PAGE, and subjected to Western blot analysis using an anti-
acetyl-lysine, anti-SIRT1, or anti-Sox9 antibodies. The original
samples were also detected using antibodies against poly(ADP-
ribose) polymerase or -actin.
Immune Complex Kinase Assay—To investigate the interplay
between SIRT1 and IB activation during chondrogenesis, an
immune complex kinase assay was performed. The IKK com-
plex was immunoprecipitated from whole cell lysates with anti-
bodies against IKK- and IKK- and subsequently incubated
with protein A/G-agarose beads (Pierce). After 2 h of incuba-
tion, the beads were washed with lysis buffer, resuspended in a
kinase assay solution containing 50 mM HEPES, pH 7.4, 20 mM
MgCl2, 2 mM dithiothreitol, 10 mM unlabeled ATP, and 2 mg of
substrate IB (amino acids 1–54), incubated at 30 °C for 30
min, and boiled in SDS-PAGE sample buffer for 5 min. SDS-
PAGE was performed under reducing conditions as described
above. Phosphorylation of IB was assessed using a specific
antibody against phosphorylated IB (Ser-32/36). To demon-
strate the total amounts of IKK- and IKK- in each sample,
whole cell lysates were transferred to a nitrocellulose mem-
brane after SDS-PAGE was performed as described above.
Detection of phosphorylated IB, IKK-, and IKK- was per-
formed by immunoblotting.
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Immunofluorescence Analysis—For double immunofluores-
cence detection of collagen type II/CSPGs and of SIRT1/Sox9,
MSC-derived chondrocytes were retrieved from alginate beads
and cultured in monolayers on glass plates for 24 h. After methanol
fixation and additional cell nucleus permeabilization with Triton
X-100 (2% in PBS) for 5 min, cells were rinsed three times with PBS
and overlaid with bovine serum albumin (1% BSA in PBS) for 1 h.
The first primary antibody incubation was performed overnight at
4 °C in a humid chamber, followed by incubation with rhodamine-
coupled secondary antibodies (diluted 1:80 in PBS) for 2 h at ambi-
ent temperature. After additional washing with 1% BSA in PBS,
cells were incubated with the second primary antibody followed by
an additional FITC-coupled secondary antibody as described
above. Finally counter-staining was performed with DAPI (Sigma)
to visualize cell nuclei, and slides were then covered with Fluoro-
mountTM mountant and examined under a fluorescent micro-
scope (Leica, Germany).
Cell Viability Assay—The cell viability was evaluated by the
MTT uptake method as described previously (42). Briefly,
MSCs in alginate culture were either left untreated or were
treated with resveratrol (5 M), NAM (10 mM), Lipofectin (10
M/ml), or were transfected with SIRT1-SO or SIRT1-ASO (0.5
M in the presence of 10 l/ml Lipofectin) for 14 days, or cells
were pretreated with resveratrol (5 M) for 4 h followed by
co-treatment with either NAM (10 mM) or transfected with 0.5
M SIRT1-SO or SIRT1-ASO in chondrogenic induction
medium for 14 days. Cells were released from alginate by dis-
solving the beads in 55 mM sodium citrate solution (1618 g of
sodium citrate in 100 ml of 0.15 M NaCl) for 20 min. Cells were
washed twice with Hanks’ balanced salt solution to remove
excess alginate and resuspended in modified cell culture
medium (DMEM without phenol red, without vitamin C, and
only 3% FBS) on a 96-well plate. 10 l of MTT solution (5
mg/ml) was immediately added to each well, and the plate was
incubated for 4 h at 37 °C. Finally, MTT solubilization solution
(10% Triton X-100/acidic isopropyl alcohol) was added, and the
cells were incubated overnight at 37 °C. Absorbance was mea-
sured at 550 nm using Revelation 96-well multiscanner plate
reader (Bio-Rad). The data obtained were calculated and were
represented as percentage of survival relative to controls. This
experiment was repeated three times independently, and statis-
tical analysis was done to obtain the final values.
Statistical Analysis—Each experiment was performed three
times as individual experiments with three replicates. For sta-
tistical analysis, a Wilcoxon-Mann-Whitney test was applied.
Score values for image quality and presence of artifacts were
compared for each sequence. A p value of 0.05 was considered
to establish statistically significant differences.
RESULTS
In this study, we evaluated the effect of resveratrol/SIRT1 on
chondrogenic differentiation of mesenchymal stem cells in an
in vitro model of chondrogenesis. The concentration of res-
veratrol or ethanol applied in our study and the time of expo-
sure had no effect on cell viability.
Characterization of MSCs—Human-derived MSCs exhibited
a polymorphic fibroblast-like phenotype (Fig. 1A, panel a). To
examine that the human MSCs (Fig. 1A) are indeed MSCs,
immunofluorescence was used to confirm positive expression
of the stem cell-specific markers (CD90 and CD105) (Fig.
1A, panels b and c). In contrast to this, they were clearly labeled
negative for the hematopoietic stem cell markers CD45 and
CD34 (Fig. 1A, panels d and e). Statistical evaluation of the
labeled cultures displayed the stem cell-specific marker-posi-
tive cell population by counting 300 cells from 10 microscopic
fields within the stained slides. As shown in Fig. 1B, this con-
firmed the results in Fig. 1A and revealed that positive expres-
sion of the stem cell-specific markers CD105 and CD90 and
negative expression of the hematopoietic lineage markers
CD45 and CD34 compared with controls (Fig. 1B).
Knockdown of SIRT1 with ASO Inhibits Differentiation of
MSCs to Chondrocytes in Vitro—To investigate whether the
specific inhibition of SIRT1 mRNA and protein expression by
ASO blocks the differentiation of MSCs to chondrocytes, we
examined ultrastructural cell morphology by transmission
electron microscopy (Fig. 2A). As positive control, high density
cultures of primary chondrocytes were performed and pre-
pared for transmission electron microscopy (Fig. 2A, panel a).
After 14 days in high density cultures, chondrocytes showed
well developed cartilage nodules with viable cells and well
developed and organized cell organelles. The cells were embed-
ded in an extensive fine fibrillar matrix tightly attached to the
cytoplasmic membrane (Fig. 2A, panel a). Untreated (Fig. 2A,
panel b) or Lipofectin-treated (data not shown) MSCs cultured
in chondrogenic induction medium for 14 days resulted in
chondrogenesis; cells exhibited high levels of nuclear euchro-
matin and large numbers of morphologically normal cellular
organelles, and the cells were embedded in a well organized
extracellular matrix (Fig. 2A, panel b). Treatment of MSC cul-
tures with the chondrogenic induction medium and SIRT1-SO
in various concentrations (0.1, 0.5, 1, and 5 M) in the presence
of Lipofectin (10 l/ml) induced chondrogenesis (Fig. 2A, pan-
els c–f). However, no significant differences in chondrogenesis
were seen at the ultrastructural level between SIRT1-SO-
treated and -untreated MSC cultures. In contrast, transfection
of MSCs with SIRT1-ASO in various concentrations (0.1, 0.5, 1,
and 5 M) in the presence of Lipofectin for 14 days revealed
inhibition of chondrogenesis. The results showed a dose-de-
pendent increase in morphological signs of degeneration and
degradation of MSCs (Fig. 2A, panels g–j). Furthermore, treat-
ment with 0.5 M or more SIRT1-ASO led to changes such as
multiple vacuoles, swelling, and degeneration of cell organelles,
and MSCs underwent apoptosis, with nuclear damage and for-
mation of apoptotic bodies (Fig. 2A, panels h–j). Statistical eval-
uation of the ultrastructural data of cells displaying severe
apoptosis was performed by counting 100 cells from 25 micro-
scopic fields. As shown in Fig. 2B, specific SIRT1-ASO effec-
tively induced cell death in a dose-dependent manner with 85%
apoptotic cells at 5 M, 83% at 1 M, 81% at 0.5 M and 28% at
0.1 M SIRT1-ASO compared with untreated cells.
Specific Inhibition of SIRT1 by SIRT1-ASO Reduces SIRT1
Protein Expression and Suppresses Cartilage-specific ECM Pro-
teins and Chondrocyte Transcription Factor Sox9 Expression
during Chondrogenesis of MSC in Vitro—Primary human chon-
drocytes were left untreated, and MSCs were either cultured
only with chondrogenic induction medium or with chondro-
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genic induction medium and transfected with different concen-
trations (0.1, 0.5, 1, and 5 M) of SIRT1-SO or SIRT1-ASO in
the presence of Lipofectin (10 l/ml) for 14 days. Whole cell
lysates were fractionated and analyzed by immunoblotting
using anti-SIRT1 (A), anti-collagen type II (B), anti-cartilage
specific proteoglycans (C), anti-cartilage-specific transcription
factor Sox9 (D), and anti--actin (Fig. 3). SIRT1 control peptide
was used as a control for antibody specificity. As shown in
Western blot analysis and densitometric evaluation, treatment
with SIRT1-ASO clearly down-regulated the expression of
SIRT1, collagen type II, CSPG proteins, and Sox9 in a dose-de-
pendent manner. The dosages of 1–5 M SIRT1-ASO almost
completely suppressed the expression of SIRT1 and Sox9 pro-
teins (Fig. 3, A–D). In contrast, Lipofectin (data not shown) and
SIRT1-SO treatment had no effect on SIRT1, collagen type II,
CSPG, and Sox9 protein levels (Fig. 3, A–D). They remained
comparable with the untreated basal control (primary human
chondrocytes), thereby highlighting the specificity of SIRT1-
ASO, suggesting that there is a connection between SIRT1 pro-
tein and chondrogenesis of MSCs.
Resveratrol Suppresses Down-regulation of ECM Proteins and
Sox9 Induced by IL-1 and NAM but Not by SIRT1-ASO during
Chondrogenesis of MSCs—Primary human chondrocytes in
high density culture were left untreated as basal control. MSCs
in high density culture were either left untreated or were
treated with resveratrol (5 M), IL-1 (10 ng/ml), NAM (10
mM), or BMS-345541 (5 M) or were transfected with
SIRT1-SO or SIRT1-ASO (0.5 M in the presence of Lipofectin
10 l/ml) for 14 days, or cells were pretreated with BMS-
345541 (5 M) for 4 h followed by co-treatment with IL-1 (10
ng/ml) for 14 days, or cells were pretreated with resveratrol (5
M) for 4 h followed by co-treatment with either IL-1 (10
ng/ml), NAM (10 mM), or BMS-345541 (5 M), or transfected
with 0.5 M SIRT1-SO or SIRT1-ASO in chondrogenic induc-
tion medium for 14 days. Whole cell lysates were fractionated
and analyzed by Western blotting with antibodies against col-
lagen type II (Fig. 4A, panel I), CSPGs (panel II), and Sox9
(panel III) (Fig. 4A). As shown in Fig. 4A, treatment of MSC
with IL-1, SIRT1 inhibitor NAM, or SIRT1-ASO alone mark-
edly suppressed collagen type II, CSPG production, and carti-
lage-specific transcription factor Sox9 during chondrogenesis
of MSCs in vitro. The basal levels of cartilage-specific matrix
expression (collagen type II and CSPGs) and Sox9 expression
were not significantly changed after incubation with BMS-
345541, resveratrol, or SIRT1-SO (Fig. 4A). However, expres-
sion of cartilage-specific ECM and Sox9 was significantly
increased in MSC cultures pretreated with resveratrol compa-
rable with control cultures but not in SIRT1-ASO treated
MSCs. This indicates that SIRT1 suppression on mRNA levels
is not reversible by resveratrol and highlights the crucial role of
SIRT1 during chondrogenesis of MSCs in vitro (Fig. 4A). More-
over, these findings suggest that there is a functional link
FIGURE 1. Characterization of MSCs. A, in monolayer culture the human MSCs (panel a) showed a polymorphic, fibroblast-like morphology. The MSCs
expressed positive stem cell-specific markers CD90 (panel b) and CD105 (panel c) and were negative for the hematopoietic stem cell markers CD45 (panel
d) and CD34 (panel e). Magnification: 10 (panel a), 40 (panels b– e), and bar, 1 m. B, to quantify the stem cell marker-positive cells, the labeled cultures were
examined by counting 300 cells from 10 microscopic fields. The examination was performed in triplicate, and the results are provided as the mean values with
S.D. from three independent experiments. Values were compared with the control, and statistically significant values with p  0.05 are designated by a star, and
p  0.01 is designated by two stars. Co., without primary antibody, followed by incubation with rhodamine-coupled secondary antibodies and counterstaining
with DAPI to visualize the cell nuclei.
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between SIRT1 protein and cartilage-specific transcription fac-
tor Sox9 and that resveratrol is able to enhance chondrogenic
MSC differentiation, at least in part, by up-regulation of Sox9
via SIRT1.
Down-regulation of SIRT1 with ASO Modulates NF-B-me-
diated Pro-inflammatory, Matrix-degrading, and Apoptotic
Gene Products during Chondrogenesis of MSC—We next
focused on the causal relationship between SIRT1 and NF-B
signaling pathways. Therefore, we used BMS-345541, which is a
potent and specific IKK complex inhibitor and can significantly
block NF-B activation induced by diverse stimuli (43). It has
been shown that BMS-345541 is a highly selective inhibitor of
IB kinase that binds at an allosteric site of the enzyme and
blocks the NF-B-dependent signal transduction pathway in
mice (43, 44). Primary human chondrocytes in high density
culture were left untreated as control. MSCs in high density
culture were either left untreated or treated as described above.
IL-1, NAM, or SIRT1-ASO induced the expression of NF-B-
dependent matrix-degrading enzymes (COX-2 and MMP-9)
and pro-apoptotic signaling (cleavage of caspase-3). Treatment
with resveratrol suppressed the expression of the mentioned
proteins in all combinations, except with SIRT1-ASO (Fig. 4B).
Furthermore, treatment with BMS-345541 alone, pretreatment
with resveratrol followed by treatment with BMS-345541, and
pretreatment with BMS-345541 followed by treatment with
IL-1 strongly stimulated the production of cartilage-specific
ECM components (Fig. 4A) and significantly decreased NF-B-
mediated degradation of ECM, as well as expression of pro-
inflammatory, matrix-degrading, and apoptotic gene products
in MSCs during chondrogenesis to levels similar to control cul-
FIGURE 2. Effects of SIRT1-ASO on chondrogenic differentiation of MCS in vitro. A, primary human chondrocytes (PCH) in high density were left untreated
(panel a). MSCs were either cultured only with chondrogenic induction medium (panel b) or with chondrogenic induction medium and simultaneously
transfected with different concentrations (0.1, 0.5, 1, 5 M) of SIRT1-SO (panels c–f) or SIRT1-ASO (panels g–j) in the presence of Lipofectin (10 l/ml). Ultra-
structural morphology of high density cultures was evaluated after 14 days by transmission electron microscope. Control cultures of chondrocytes or MSCs or
treatment of MSCs with SIRT1-SO showed well developed chondrocytes (Ch) embedded in a well developed ECM and the formation of cartilage nodules
(panels a–f). Treatment with SIRT1-ASO resulted in matrix breakdown and cell lysis and apoptosis (arrows) (panels g–j). Micrographs shown are representative
of three individual experiments. Magnification: 5000, bar, 1 m. B, to quantify degenerative changes, high density cultures of A were examined for apoptosis
by counting 100 cells from 25 microscopic fields. The examination was performed in triplicate, and the results are provided as the mean values with S.D. from
three independent experiments. Values were compared with the control and statistically significant values with p  0.05 were designated by a star and p  0.01
were designated by a two stars.
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tures (Fig. 4B). Taken together, these results demonstrate that
the IKK inhibitor (BMS-345541) suppresses, in a similar way to
resveratrol, the destructive effects of IL-1 and that IKK, at
least in part, is one of the kinases that play an important role in
resveratrol/SIRT1 signaling pathways during chondrogenesis.
Knockdown of SIRT1 with ASO Enhances NF-B Acetylation
and Phosphorylation during Chondrogenesis of MSCs in Vitro—
Acetylation and phosphorylation of p50/p65 play an important
role in IB-mediated activation of NF-B transcriptional
activity (45, 46); therefore, we investigated the effect of resvera-
trol on the induction of NF-B acetylation and phosphorylation
by IL-1, NAM, and SIRT1-ASO. Primary human chondro-
cytes in high density culture were left untreated as control.
MSCs in high density culture were either left untreated or
treated as described above. Immunoblotting of whole cell
lysates was performed using anti-acetylated lysine and anti-
phosphorylated NF-B (Fig. 5). As shown in Fig. 5A, treatment
with IL-1, NAM, or SIRT1-ASO alone markedly increased
acetylation and phosphorylation of the NF-B-p65 subunit in
MSCs during chondrogenesis in vitro. In contrast to this, pre-
treatment with resveratrol blocked NF-B acetylation and
phosphorylation during chondrogenesis of MSCs in all groups,
except in cells treated with SIRT1-ASO. These findings indicate
that down-regulation of SIRT1 on the protein level by the
SIRT1 inhibitor NAM or on the mRNA level by ASO induces an
equal inflammatory response as shown by stimulation with pro-
inflammatory cytokine IL-1. Furthermore, resveratrol can
block this inflammation signaling through activation of SIRT1
if down-regulation of SIRT1 was induced at the protein level
but not at the gene level. Additionally, treatment with the spe-
cific NF-B pathway inhibitor BMS-345541 alone or pretreat-
ment with resveratrol or BMS-345541 followed by stimulation
with IL-1 resulted in suppression of cytokine-induced effects
on NF-B acetylation and phosphorylation during chondro-
genesis of MSCs. These results indicate that IKK is the one of
the upstream kinases involved in resveratrol-mediated signal-
ing to inhibit NF-B activation (Fig. 5).
SIRT1 Associates and De-acetylates NF-B-p65 during Chon-
drogenesis of MSCs in Vitro—The above data show that stimu-
lation of SIRT1 enzymatic activity correlated with increased
de-acetylation of NF-B, suggesting that both proteins interact
together during chondrogenesis of MSCs in vitro. Therefore,
next we performed a co-immunoprecipitation assay to evaluate
association of SIRT1 and NF-B during chondrogenesis of
MSCs in vitro (Fig. 5B). Primary human chondrocytes in high
density culture were left untreated as control. MSCs in high
density culture were either left untreated or treated as
described above. Whole cell extracts were immunoprecipitated
with anti-SIRT1 and then probed for anti-acetyl-lysine by
Western blotting. As shown in Fig. 5B, SIRT1 was strongly co-
FIGURE 3. Effects of SIRT1-ASO on SIRT1 expression, ECM protein production, and cartilage-specific transcription factor Sox9 during chondrogenesis
of MSC in vitro. Primary human chondrocytes (PCH) in high density were left untreated. MSCs in high density were either cultured only with chondrogenic
induction medium or with chondrogenic induction medium and transfected with different concentrations of SIRT1-SO or SIRT1-ASO (0.1, 0.5, 1, and 5 M) in the
presence of Lipofectin (10 l/ml) for 14 days. Whole cell lysates were prepared and analyzed by Western blotting with antibodies against SIRT1 (A), collagen
type II (B), cartilage-specific proteoglycans (C), and cartilage-specific transcription factor Sox9 (D). Densitometric evaluation of protein expression as revealed
by Western blot analysis was performed in triplicate. Bars represent the mean values ( S.D.) for collagen type II of the 216-, 137-, and 110-kDa bands and for
cartilage-specific proteoglycans of the 140-, 127-, and 33-kDa bands. SIRT1 control peptide (Co. Pep) was used as a control for SIRT1 antibody specificity. The
results shown are representative of three independent experiments. Housekeeping protein -actin served as a loading control in all experiments. The arrows
in the right margin indicate the relative position of the proteins and molecular mass markers (left margin) are indicated in kDa. Values were compared with the
control and statistically significant values with p  0.05. Significant values are marked with a star.
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immunoprecipitated with acetylated NF-B in cultures treated
with IL-1, NAM, or SIRT1-ASO. In contrast, pretreatment of
cultures with resveratrol followed by co-treatment with IL-1,
NAM, or SIRT1-ASO strongly inhibited acetylation of NF-B
subunits (p50/p65) in IL-1 and NAM but weaker in SIRT1-
ASO cultures, suggesting that resveratrol effectively blocks
activation of NF-B signaling pathways by modulating acetyla-
tion. Taken together, these findings indicate that SIRT1 inhibi-
tion on mRNA levels is not reversible by resveratrol, highlight-
ing the crucial role of SIRT1 in inhibiting the NF-B pathway.
Interestingly, in resveratrol-pretreated cultures followed by
treatment with SIRT1-ASO, marginal SIRT1 co-immunopre-
cipitation with acetylated NF-B was observed. To determine
whether BMS-345541, the specific inhibitor of IKK, can inhibit
the NF-B pathway like resveratrol, cells were treated with
BMS-345541 alone or pretreated with resveratrol or BMS-
345541 followed by stimulation with IL-1. This resulted in an
inhibition of acetylation of NF-B subunits (p50/p65) (Fig. 5B).
These findings demonstrate that the two proteins (NF-B and
SIRT1) interact with each other and that NF-B may be a sub-
strate for SIRT1 deacetylase in MSCs during MSC chondrogen-
esis. Taken together, these results indicate that resveratrol-in-
duced SIRT1 forms a complex with NF-B, de-acetylating
NF-B, thereby suppressing NF-B-mediated production of
inflammatory gene end products and enhancing chondrogene-
sis of MSCs in vitro.
Resveratrol Suppresses IB Kinase Activation Induced by
IL-1 and NAM but Not by SIRT1-ASO during Chondrogenesis
of MSC—Next, we evaluated the effect of SIRT1 on IB kinase
(IKK) activation, which is required for phosphorylation of IB
and subsequently NF-B signaling pathway activation. Primary
human chondrocytes in high density culture were left untreated
FIGURE 4. Effects of resveratrol, IL-1, NAM, BMS-345541, and SIRT1-ASO on ECM protein, Sox9, and NF-B-dependent proinflammatory, matrix-degrad-
ing, and apoptotic gene products during chondrogenesis of MSC in vitro. A, primary human chondrocytes (PCH) in high density culture were left untreated as
control. MSCs in high density culture were either left untreated or treated with resveratrol (5 M), IL-1 (10 ng/ml), NAM (10 mM), BMS-345541 (5 M) or were
transfected with SIRT1-SO or SIRT1-ASO (0.5 M) in the presence of Lipofectin (10 l/ml) for 14 days, or cells were pretreated with BMS-345541 (5 M) for 4 h followed
by co-treatment with IL-1 (10 ng/ml) for 14 days. Other cultures were pretreated with resveratrol (5 M) for 4 h followed by co-treatment with IL-1 (10 ng/ml), NAM
(10 mM), or BMS-345541 (5 M) or transfected with 0.5 M SIRT1-SO, SIRT1-ASO in chondrogenic induction medium for 14 days. Whole cell lysates (500 ng of
protein/lane) were prepared and analyzed by Western blotting with antibodies against collagen type II (panel I), cartilage-specific proteoglycans (panel II), and Sox9
(panel III). B, same MSC cultures as in A were subsequently also probed for expression of COX-2 (panel I), MMP-9 (panel II), and cleavage of caspase-3 (panel III).
Densitometric evaluation of protein expression as revealed by Western blot analysis was performed in triplicate. Housekeeping protein -actin served as a loading
control in all experiments. Values were compared with the control and statistically significant values with p  0.05. Significant values are marked a star.
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as control. MSCs in high density culture were either left
untreated or treated as described above (Fig. 4A). Whole cell
extracts were immunoprecipitated with an antibody against
IB kinase (IKK- and IKK-) and then analyzed by an immune
complex kinase assay for phosphorylation of IB. As shown in
Fig. 5C, IKK- and IKK- were equally detected in all samples,
proving that immunoprecipitation was successful. Treatment
with IL-1, NAM, or SIRT1-ASO led to marked activation of
IB. No phosphorylated IB was found in basal control (pri-
mary human chondrocytes), resveratrol-, and SIRT1-SO-
treated cultures. Co-treatment with the SIRT1 activator res-
veratrol, similar to control cultures, blocked IB activation in
IL-1- or NAM-treated but not in SIRT1-ASO-treated cells,
suggesting that SIRT1 suppression on mRNA levels is not
reversible by resveratrol. Pretreatment of cultures with BMS-
345541 or resveratrol followed by stimulation with IL-1
resulted in an inhibition of activation of IKK (Fig. 5C). IL-1,
BMS-345541, and resveratrol had no direct effect on the
expression of IKK- and IKK- proteins. These findings indi-
cate that SIRT1 inhibits the IB phosphorylation/NF-B sig-
naling pathway and highlights the important functional role of
SIRT1 in inhibiting NF-B pathway.
Interaction of SIRT1 with the Master Chondrogenic Tran-
scription Factor Sox9 Is Stimulated by Resveratrol during Chon-
drogenesis of MSCs in Vitro—It has been reported that resvera-
trol is a specific potent activator of histone deacetylase SIRT1
(47). To examine the downstream signaling pathway during
MSC chondrogenesis, we investigated whether SIRT1 associ-
ates with the chondrogenic transcription factor Sox9 and sub-
sequently stimulates chondrogenesis. To this end, primary
human chondrocytes (served as control) or MSCs in alginate
culture were either left untreated or were treated with resvera-
trol (5 M) for 4 h alone or were transfected with 0.5 M
SIRT1-SO or SIRT1-ASO and cultured with chondrogenic
induction medium (Fig. 6). After 14 days, whole cell extracts
were immunoprecipitated with anti-SIRT1 and analyzed by
Western blotting with antibodies against Sox9. Interestingly,
immunoprecipitates from chondrocytes or MSCs in untreated
controls, SIRT1-SO- or resveratrol-treated cultures, but not
from SIRT1-ASO-treated cultures, revealed co-immunopre-
cipitation of SIRT1 protein with the chondrogenic transcrip-
tion factor Sox9 (Fig. 6A). Furthermore, treatment with the
natural SIRT1 activator resveratrol markedly increased
interaction and co-immunoprecipitation of SIRT1 and Sox9
in MSCs during chondrogenesis as well as in chondrocyte
controls as shown by densitometric analysis. Moreover, the
same samples were immunoprecipitated with anti-Sox9 and
analyzed by Western blotting with antibodies against SIRT1
and showed a complex formation between SIRT1 and Sox9
(Fig. 6B). Taken together, these findings indicate that res-
veratrol activates SIRT1 and induces SIRT-Sox9 complex
formation, which may activate the chondrogenic differenti-
ation pathway in MSCs.
Co-localization of SIRT1 and Sox9 Is Required during Chon-
drogenesis of MSCs in Vitro—Based on the immunoprecipita-
tion and Western blotting results (Fig. 6) and to confirm them,
FIGURE 5. Effects of resveratrol, IL-1, NAM, BMS-345541, and SIRT1-ASO on NF-B signaling pathway during chondrogenesis of MSC in vitro. The
same primary human chondrocytes (PCH) and MSC cultures as in Fig. 4A were subsequently subjected to Western blotting with antibodies against acetyl-lysine,
p-NF-B, and -actin (A). Whole cell lysates were immunoprecipitated (IP) for SIRT1 and then subjected to Western blotting with antibodies against acetyl-
lysine. The original samples were probed with an antibody to anti-poly(ADP-ribose) polymerase (PARP) as a loading control (B). Whole cell lysates were
immunoprecipitated for IKK and analyzed by an immune complex kinase assay as described under “Experimental Procedures” (C). The level of activation of IKK
proteins was then determined by Western blotting using anti-IKK-, anti-IKK-, and anti-phospho-specific IB antibodies. The results shown are representative
of three independent experiments. IB, immunoblot.
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we performed immunofluorescence analysis. MSCs were
induced toward the chondrogenic lineage in three-dimensional
alginate cultures with chondrogenic induction medium for 14
days. Newly formed chondrocytes were dissolved from alginate
and cultivated in monolayer culture. Chondrogenic phenotype
of the differentiated MSCs was confirmed by double immuno-
fluorescent labeling with anti-collagen type II and anti-CSPGs
(Fig. 7I, panels a and b). To examine whether inhibition of
SIRT1 and/or Sox9 expression with specific SIRT1-ASO can be
visualized by immunofluorescence, newly differentiated chon-
drocytes in monolayer culture were either left untreated or
treated with resveratrol (5 M), NAM (10 mM), or with
SIRT1-SO or SIRT1-ASO (0.5 M) in the presence of Lipofectin
for 24 h, or the cells were pretreated with resveratrol (5 M) for
1 h followed by co-treatment with NAM (10 mM) for 1 h,
SIRT1-SO (data not shown), or SIRT1-ASO (0.5 M) in the
presence of Lipofectin for 24 h (Fig. 7II). Double immunolabel-
ing was performed with primary antibodies to SIRT1 and Sox9,
followed by incubation with rhodamine- or FITC-coupled sec-
ondary antibodies. Counterstaining was performed with DAPI
to visualize the cell nuclei. Double immunofluorescence analy-
sis showed that in untreated cultures (control culture, co) or
cultures treated with SIRT1-SO (data not shown), marked
expression of SIRT1 and Sox9 and nuclear co-localization of
these two proteins were observed (Fig. 7II, panels a– c). Treat-
ment with natural SIRT1 activator resveratrol, SIRT1-SO alone
(data not shown), or resveratrol in combination with SIRT1-SO
(data not shown) strongly induced SIRT1 and Sox9 activation
in the nucleus (Fig. 7II, panels d–f). In contrast to this, treat-
ment with NAM (Fig. 7II, panels g–i) or SIRT1-ASO (Fig. 7II,
panels j–l) reduced the levels of SIRT1 and Sox9 expression and
nuclear localization. However, co-treatment of resveratrol and
NAM recovered SIRT1 and Sox9 nuclear expression and co-lo-
calization (Fig. 7II, panels m– o). Interestingly, in cultures
treated with SIRT1-ASO and resveratrol, co-treatment could
marginally restore SIRT1 and Sox9 expression as seen by spo-
radic nuclear co-localization of SIRT1/Sox9 (Fig. 7II, panels
p–r). Furthermore, merged images clearly demonstrate nuclear
co-localization of SIRT1/Sox9, underlining the importance of
SIRT1/Sox9 nuclear co-localization during chondrogenic signal-
ing in MSCs in vitro. Quantification and statistical analysis of the
immunomorphological data highlight the prominent effects of
specific SIRT1 inhibition and/or activation on Sox9 expression in
MSC-derived chondrocytes in vitro (Fig. 7III).
Resveratrol Suppresses Down-regulation of Specific MSC
Chondrogenic Differentiation Induced by NAM but Not by
SIRT1-ASO in Alginate Culture—Studies from our laboratory
have previously shown that in alginate culture only cells with
chondrogenic potential can survive and alginate functions as a
selective filter station separating vital from nonvital chondro-
FIGURE 6. Association of SIRT1 proteins with Sox9 during chondrogenic differentiation of MSC in vitro. Primary human chondrocytes (PCH) or MSC in
alginate culture were either left untreated (Co.) or treated for 4 h with resveratrol (5 M), or transfected with 0.5 M SIRT1-SO or SIRT1-ASO in the presence of
Lipofectin (10 l/ml), and cultured with chondrogenic induction medium. After 14 days, whole cell extracts were lysed and immunoprecipitated (IP) with SIRT1
(A), or with Sox9 (B); subsequently the immunoprecipitates were separated by SDS-PAGE and analyzed by immunoblotting (IB) using anti-Sox9 (A) and
anti-SIRT1 (B). Densitometric evaluation of protein expression as revealed by Western blot analysis was performed in triplicate. The original samples were
probed with an antibody to -actin as a loading control. Each experiment was performed in triplicate, and mean values and standard deviations are indicated.
Values were compared with the control and statistically significant values with p  0.05 were designated by a star. M, marker for molecular weights. IgH,
immunglobulin heavy chain.
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cytes and fibroblasts (10, 14, 48). To assess the potential of MSC
chondrogenic differentiation, the inhibition of this differentia-
tion by specific SIRT1 inhibitors, the inductive function of res-
veratrol in this process, and the viability of the survived cells,
MSCs in alginate culture were either left untreated or were
treated with resveratrol (5 M), NAM (10 mM), Lipofectin (10
M/ml), or transfected with SIRT1-SO or SIRT1-ASO (0.5 M
in the presence of Lipofectin 10 M/ml) for 14 days. Addition-
ally, in another set of experiments, cells were pretreated with res-
veratrol (5 M) for 4 h followed by transfection with 0.5 M
SIRT1-SO or SIRT1-ASO or co-treatment with NAM (10 mM) in
chondrogenic induction medium. After 14 days of culture, cells
were dissolved from alginate, and cell viability was measured with
the MTT method. As shown in Fig. 8, treatment of MSC with the
SIRT1 inhibitor NAM or SIRT1-ASO alone markedly reduced
MSC viability during chondrogenesis of MSCs compared with
controls or with resveratrol-treated cells. However, pretreatment
with resveratrol blocked inhibition of MSC chondrogenic differ-
entiation and viability induced by NAM, but not by SIRT1-ASO
(Fig. 8). Taken together, MSCs treated with SIRT1 inhibitors
(NAM or SIRT1-ASO), as opposed to controls or with resveratrol-
treated MSCs, were not able to survive in alginate cultures, and
they underwent cell death.
DISCUSSION
The goal of this study was to examine the role of SIRT1-
mediated signaling during chondrogenic differentiation of
mesenchymal stem cells in an in vitro model of chondrogenesis.
Cartilage tissue has a very limited capacity for spontaneous
healing or repair after articular cartilage defects (micro- or
macrotrauma), presenting an increasing problem for humans
and animals, which necessitates the development of novel and
improved therapeutic strategies (49). Moreover, cartilage tissue
engineering from primary chondrocytes is to date unsatisfac-
tory, mainly due to the fact that the long culturing period leads
to dedifferentiation of chondrocytes. Therefore, using MSCs as
an important source for cartilage tissue engineering has
become a highly investigated area of biology and regenerative
medicine (4). MSCs are multipotent cells with a stable pheno-
type and self-renewal capacity that can differentiate into differ-
ent specialized cell lineages (i.e. osteoblasts, chondroblasts,
myoblasts, adipocytes, etc.) (1, 2). Furthermore, they can be
easily isolated and expanded several times without losing their
specific properties. MSCs have been transferred into osteo-
chondral defects, integrated into the subchondral plate, and
produced proper ECMs in a rabbit model (50). However, little is
known about the biological behavior of MSCs during chondro-
genic differentiation. Therefore, we investigated the potential
role of resveratrol (natural SIRT1 activator) on chondrogenic
differentiation of MSCs through its effects on SIRT1-mediated
cellular responses in three-dimensional models of chondrogen-
esis in vitro. Because resveratrol is a component of a wide vari-
ety of vegetables and fruits actively consumed by most people, it
is preferable to examine the mechanism of action of resveratrol.
Although more potent activators of SIRT1 have become avail-
FIGURE 7. Effects of resveratrol, NAM, and SIRT1-ASO on the co-localization of SIRT1 and Sox9 in MSC-derived chondrocytes revealed by immuno-
fluorescence microscopy. Chondrogenic differentiation of MSC was performed in three-dimensional alginate cultures with chondrogenic induction medium
for 14 days. Differentiated chondrocytes were dissolved from alginate and transferred to monolayer culture for additional treatment. I, chondrocytes were
double-immunolabeled with primary antibodies to collagen type II (panel a) and CSPGs (panel b) to confirm chondrogenic lineage. Magnification 400; bars,
30 nm. II, chondrocytes were either left untreated (panels a– c) or treated with 5 M resveratrol (panels d–f), 10 mM NAM (panels g–i) alone for 1 h, 0.5 M SIRT1-SO
(data not shown), or SIRT1-ASO (panels j–l) in the presence of Lipofectin (10 l/ml) for 24 h or cells were pretreated with resveratrol (5 M) for 1 h followed by
co-treatment with 10 mM NAM (panels m– o) for 1 h, 0.5 M SIRT1-SO (data not shown), or SIRT1-ASO (panels p–r) in the presence of Lipofectin (10 l/ml) for 24 h.
Double immunolabeling was performed for SIRT1 and Sox9. Magnification 400; bars, 30 nm. III, to quantify co-localization of SIRT1 and Sox9, monolayer
cultures were examined for nucleus positive cells by counting 100 cells randomly and evaluating the number of positively stained cells. The results are provided
as mean values with standard deviations from at least three independent experiments. Values were compared with the control and statistically significant
values with p  0.05. Significant values are marked with star.
FIGURE 8. Effects of resveratrol, NAM, and SIRT1-ASO on the chondrogenic differentiation of MSC and chondrocyte viability in alginate culture. MSCs
in alginate were either left untreated or treated with 5 M resveratrol, 10 mM NAM, or 10 l/ml Lipofectin alone or were transfected with 0.5 M SIRT1-SO or
SIRT1-ASO in the presence of Lipofectin (10 l/ml), or cells were pretreated with 5 M resveratrol for 4 h followed by co-treatment with 10 mM NAM or were
transfected with 0.5 M SIRT1-SO or SIRT1-ASO in chondrogenic induction medium. After 14 days of culture, cells were dissolved from alginate and cell viability
was measured with the MTT method. The results are provided as mean values with standard deviations from at least three independent experiments. Values
were compared with the control and statistically significant values with p  0.05. Significant values are marked with star.
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able, they are excellent for understanding the mechanism but
may not be suitable to be consumed every day.
In this study, SIRT1-ASO, like NAM or IL-1, enhanced
cartilage-specific ECM breakdown, down-regulated the
expression and activation of SIRT1 protein and of the cartilage-
specific transcription factor Sox9, and up-regulated NF-B-
regulated pro-inflammatory and pro-apoptotic proteins during
chondrogenic differentiation of MSCs. However, pretreatment
of MSCs with resveratrol or BMS-345541 led to the recovery of
chondrogenic MSC differentiation, increased production of
ECM, and expression of Sox9 and inhibited pro-inflammatory
proteins in IL-1- or NAM-stimulated MSCs but not in with
SIRT1-ASO-treated cultures. Thus, SIRT1 and NF-B appear
to be important modulators during chondrogenic differentia-
tion of MSC. In fact, several lines of evidence have shown that
resveratrol is a suppressor of the NF-B transcription factor
(51, 52), a potent activator of SIRT1 in chondrocytes (47, 53).
SIRT1 has regulatory effects on cell differentiation, prolifera-
tion, survival, and organism longevity (47, 54 –56). Further-
more, our laboratory and others have previously reported that
resveratrol is an inhibitor of the pro-inflammatory cytokine
IL-1, highlighting that resveratrol suppressed IL-1-induced
activation of NF-B and NF-B-dependent gene products (51,
57, 58). Indeed, we have also shown that resveratrol inhibited
IL-1-induced apoptosis in tenocytes, and this was linked to
changes in the expression of p53, Bax, and caspase-3 (38). How-
ever, the mechanisms regulating the suppressive signaling of res-
veratrol on IL-1-induced NF-B transcriptional activity have not
yet been fully understood. Opposite to this, several lines of evi-
dence have also reported that resveratrol induces apoptotic cell
death in several tumor cell lines through the stimulation of
caspase-3, accumulation of p53 and p21, and cleavage of poly-
(ADP-ribose) polymerase (51, 59, 60). There may be different and
multiple reasons for these diverse findings. It should be considered
that phytochemicals can interact differently in diverse cell types,
species, and stimulants, various cellular stress responses, and
many others. Furthermore, the concentration of resveratrol and
the period of time the cells are exposed to resveratrol should be
considered as this additionally may cause variable effects.
We further found that during chondrogenic differentiation
of MSCs, knockdown of SIRT1 by ASO, like NAM or IL-1,
caused NF-B activation, and this was mediated through stim-
ulation of IKKs, which led to up-regulation of phosphorylated
I-B. However, pretreatment with resveratrol inhibited IKK
activation by NAM or IL-1 but not by SIRT1-ASO. Indeed,
activation of NF-B is primarily regulated by the interaction of
inhibitory proteins, such as IB and IKKs (61), and activation
of IKKs leads to activation of NF-B independent of NF-B-
inducing kinase (62). Our results further demonstrated that
MSC pretreatment with the specific IKK inhibitor BMS-
345541, which was followed by stimulation with IL-1, revealed
a significant increase in cartilage-specific matrix expression
and Sox9 expression and exhibited a significant decrease in
NF-B-related gene end products (MMP-9, COX-2 expression,
and caspase-3 cleavage) in a similar way to resveratrol. These
findings showed that IKK-mediated NF-B activation is stimu-
lated by SIRT1-ASO, IL-1, and NAM, indicating that IKK is
one of the main upstream stimulatory kinases that may be mod-
ulated by SIRT1 and that could play a major role in resveratrol/
SIRT1-mediated signaling pathways during chondrogenic dif-
ferentiation of MSCs in vitro. Moreover, inhibition of SIRT1
during differentiation of MSCs to chondrocytes by all inhibitors
used in this study stimulated activation of IKK, phosphoryla-
tion of IB, p65 phosphorylation, and acetylation. This was
correlated with up-regulation of NF-B-regulated gene prod-
ucts involved in degradation, inflammation, and apoptosis. Res-
veratrol recovered the IL-1- or NAM-induced up-regulation
of various NF-B-regulated gene products but not the effects of
SIRT1-ASO. These data further suggest that resveratrol sup-
presses NAM-induced NF-B acetylation through SIRT1 acti-
vation. Moreover, these findings strongly indicate that down-
regulation of SIRT1 by mRNA interference abrogates its
suppressive effects on NF-B, indicating the essential role and
function of SIRT1 for chondrogenic differentiation and survival
of MSC. Furthermore, several reports have shown that SIRT1
deacetylates lysine residues of histone proteins and other
nuclear proteins and transcription factors linked with apopto-
sis and inflammation, such as p53 (38, 63) and NF-B subunit
p65 (38, 64), thereby regulating transcriptional activity of target
proteins. Interestingly, it has been reported that deacetylation
of NF-B by SIRT1 suppresses DNA binding that leads to a loss
of transactivation potential (45). However, to our knowledge,
this result is the first evaluation that shows the effects of SIRT1-
ASO on NF-B activation in MSC during chondrogenesis.
We also showed that the positive effect of resveratrol on
chondrogenic differentiation of MSC was, at least in part, reg-
ulated by activation of Sox9 as a marker for chondrogenic via-
bility. Indeed, immunoprecipitation, Western blotting, and
immunofluorescence microscopy results clearly revealed func-
tional and physical interactions between Sox9 and SIRT1,
highlighting that this interaction may play an important role in
regulating resveratrol-activated SIRT1 during MSC chondro-
genesis. Thus, Sox9 appears to be a substrate to SIRT1, and in
this way SIRT1 might contribute, at least in part, to the specific
induction of MSC differentiation to chondrocytes and mainte-
nance of MSC phenotypes by regulation of the transcription
factors such as Sox9.
Supporting our data, a recent report showed that SIRT1
interacts directly with the master cartilage-specific transcrip-
tion factor Sox9 in differentiated chondrocytes, stimulating
transcriptional activity of the collagen promoter in a Sox9-de-
pendent fashion (65). Moreover, SIRT1 plays an important role
in the regulation of genome architecture and gene expression
(29, 66). Interestingly, MSC derived from SIRT1 knock-out
mice showed clearly reduced chondrogenic potential in vitro
(67). Indeed, these results are consistent with earlier reports dem-
onstrating that SIRT1 is able to interact with other transcription
factors, like Runx2 in osteoblasts or scleraxis in tenocytes (38, 62,
68) or p53, NF-B, myogenic differentiation, high mobility group I,
E2F transcription factor, peroxisome proliferator-activated recep-
tor-, and forkhead box O (27, 28, 30, 69).
In this study, we also found that knockdown of SIRT1 by
SIRT1-ASO, like NAM, opposite the control or with resvera-
trol-treated MSCs, inhibited the chondrogenic differentiation
of MSCs in alginate beads as was demonstrated by reduced cell
viability in MTT assay. With these results in the alginate culture
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system, we could show additionally the specific differentiation
of MSCs to chondrocytes, and here, only the cells with chon-
drogenic potential survive. These results indicate the suitability
of the alginate culture as an adequate microenvironment for
chondrogenic differentiation of MSCs, and MSCs that survived
during chondrogenic differentiation in the presence of different
agents in alginate can only be chondrocytes. Indeed, the algi-
nate culture system employed here has been successfully used
as a model for chondrogenic differentiation, and alginate acts as
a selective filter station separating vital from nonvital chondro-
cytes and fibroblasts (10, 14, 48).
In summary, the results obtained strongly suggest that
SIRT1, at least in part, may inhibit NF-B signaling via deacety-
lation and IKK inhibition, demonstrating a novel role for
resveratrol in chondrogenic differentiation of MSCs. Further-
more, this study identified that during chondrogenic differen-
tiation of MSC, Sox9 and SIRT1 directly interact together and
revealed a positive cooperation by inhibiting inflammatory sig-
naling and enhancing expression of cartilage-specific ECM in
vitro. Further studies will be required to examine the full diver-
sity of the effects of resveratrol/SIRT1-mediated signaling and
its important role for the differentiation of MSCs to chondro-
cytes, and these results may reveal new insights for cartilage
tissue regeneration.
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